摘要1文献类型
治疗。
2证据水平
1a。
3文献来源
Tsao MS, Sakurada A, Cutz JC, et al, Erlotinib in lung cancer-molecular and clinical predictors of outcome [J]. N Engl J Med, 2005,353： 133-134,
1Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350:2129-2139.
2Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy[J].Science,2004,304:1497-1500.
3Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from "never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101:13306-13311.
4Cappuzzo F,Hirsch FR,Rossi E,et al.Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall-cell lung cancer[J].J Natl Cancer Inst,2005,97:643-655.
6Brehmer D,Gref Z,Gedl K,et al.Celular targets if gefltinib[J].Cancer res,2005,65:379-382.
7Viswanathan A,Pilot G,Govindan R.Lack of response to erlotinib after progression on gefitinlb in patients with advanced non-small cell lung Cancer[J].Lung Cancer,2005,50(3):417-418.
8Garfield DH.Modern treatment of lung cancer:case 2.Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma[J].Clin Oncol,2005,23(30):7738-7740.
9Tammaro KA,Baldwin PD,Lundberg AS.Interstitial lung disease folowing erlotinib(Tarceva)in a patient who previously tolerated gefitinib(Iressa)[J].Oncol Pharm Pract,2005,11(3):127-130.
10Jemal A,Siegel R,Ward E,et al.Cancer statistics,2006.CA Cancer J Clin,2006,56 (2):106-130.
